KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Depreciation and Depletion (2016 - 2025)

West Pharmaceutical Services' Depreciation and Depletion history spans 17 years, with the latest figure at $46.4 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 16.58% year-over-year to $46.4 million; the TTM value through Dec 2025 reached $168.6 million, up 11.07%, while the annual FY2025 figure was $168.6 million, 11.07% up from the prior year.
  • Depreciation and Depletion for Q4 2025 was $46.4 million at West Pharmaceutical Services, up from $42.3 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $46.4 million in Q4 2025 and bottomed at $27.7 million in Q2 2021.
  • The 5-year median for Depreciation and Depletion is $34.1 million (2023), against an average of $34.4 million.
  • The largest annual shift saw Depreciation and Depletion fell 6.81% in 2022 before it increased 20.42% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $32.3 million in 2021, then dropped by 6.81% to $30.1 million in 2022, then rose by 14.95% to $34.6 million in 2023, then increased by 15.03% to $39.8 million in 2024, then rose by 16.58% to $46.4 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Depreciation and Depletion are $46.4 million (Q4 2025), $42.3 million (Q3 2025), and $40.8 million (Q2 2025).